Skip to main content
. 2021 Apr 14;2021:6686167. doi: 10.1155/2021/6686167

Table 2.

Subgroup analyses for obliteration rate, rehemorrhage rate, and permanent neurological deficits.

Outcomes Factors Groups No. of studies OR and 95% CI P value I 2 (%) P Q statistic P value between subgroups
Obliteration rate Study design Prospective 2 1.18 (0.45-3.08) 0.731 0.0 0.946 0.188
Retrospective 16 0.54 (0.41-0.71) < 0.001 68.8 < 0.001
Country Eastern 6 0.57 (0.41-0.79) 0.001 0.0 0.446 0.538
Western 12 0.55 (0.39-0.77) < 0.001 75.4 < 0.001
Sample size ≥ 100 8 0.58 (0.40-0.84) 0.004 84.3 < 0.001 0.358
< 100 10 0.53 (0.37-0.76) 0.001 0.0 0.878
Mean age (years) ≥ 30 13 0.55 (0.39-0.77) 0.001 74.9 < 0.001 0.872
< 30 5 0.64 (0.48-0.86) 0.003 0.0 0.724
Nidus volume (ml) ≥ 10 6 0.56 (0.34-0.91) 0.020 0.0 0.823 < 0.001
< 10 10 0.48 (0.38-0.61) < 0.001 39.4 0.095
Margin dose (Gy) ≥ 20 8 0.53 (0.39-0.72) < 0.001 56.7 0.024 < 0.001
< 20 8 0.58 (0.39-0.87) 0.009 53.8 0.034
Intervention Linear accelerator 4 0.47 (0.30-0.73) 0.001 0.0 0.789 < 0.001
Gamma knife surgery 9 0.49 (0.38-0.64) < 0.001 45.4 0.066
Not mentioned 5 0.96 (0.79-1.17) 0.688 0.0 0.624
Follow-up (months) ≥ 60 9 0.59 (0.41-0.86) 0.006 80.3 < 0.001 0.036
< 60 9 0.48 (0.37-0.63) < 0.001 0.0 0.778
Study quality High 11 0.52 (0.38-0.72) < 0.001 77.7 < 0.001 0.492
Low 7 0.73 (0.46-1.16) 0.182 0.0 0.618
Rehemorrhage rate Study design Prospective 1 0.40 (0.04-3.86) 0.428 — — 0.395
Retrospective 9 1.05 (0.81-1.37) 0.708 11.1 0.343
Country Eastern 3 1.86 (0.30-11.58) 0.507 51.1 0.129 0.777
Western 7 1.06 (0.86-1.30) 0.583 0.0 0.476
Sample size ≥ 100 5 1.10 (0.89-1.34) 0.373 0.0 0.977 0.208
< 100 5 0.71 (0.21-2.42) 0.583 47.8 0.105
Mean age (years) ≥ 30 9 1.09 (0.89-1.33) 0.418 0.0 0.565 0.085
< 30 1 0.23 (0.04-1.33) 0.100 — —
Nidus volume (ml) ≥ 10 2 1.87 (0.02-153.75) 0.780 85.2 0.009 0.881
< 10 6 1.03 (0.72-1.49) 0.864 0.0 0.854
Margin dose (Gy) ≥ 20 3 1.13 (0.75-1.70) 0.569 0.0 0.882 0.833
< 20 5 0.85 (0.38-1.92) 0.701 53.9 0.070
Intervention Linear accelerator 1 0.37 (0.07-1.99) 0.247 — — 0.464
Gamma knife surgery 5 1.09 (0.75-1.58) 0.665 0.0 0.976
Not mentioned 4 0.93 (0.25-3.37) 0.909 61.1 0.052
Follow-up (months) ≥ 60 6 1.07 (0.68-1.69) 0.763 32.4 0.193 0.496
< 60 4 0.91 (0.56-1.48) 0.712 0.0 0.604
Study quality High 5 1.08 (0.88-1.32) 0.451 0.0 0.731 0.474
Low 5 0.87 (0.23-3.27) 0.841 44.3 0.127
Permanent neurological deficits Study design Prospective 0 — — — — —
Retrospective 7 0.80 (0.48-1.33) 0.385 18.8 0.286
Country Eastern 2 0.69 (0.13-3.67) 0.663 0.0 0.981 0.898
Western 5 0.84 (0.44-1.59) 0.585 45.8 0.117
Sample size ≥ 100 5 0.89 (0.42-1.86) 0.751 41.2 0.146 0.650
< 100 2 0.64 (0.27-1.55) 0.325 0.0 0.537
Mean age (years) ≥ 30 6 0.81 (0.46-1.44) 0.480 32.3 0.194 0.926
< 30 1 0.67 (0.04-11.73) 0.784 — —
Nidus volume (ml) ≥ 10 1 0.54 (0.19-1.53) 0.245 — — 0.562
< 10 5 0.83 (0.38-1.80) 0.631 35.9 0.182
Margin dose (Gy) ≥ 20 4 0.81 (0.30-2.17) 0.674 50.9 0.106 0.774
< 20 3 0.83 (0.42-1.65) 0.591 0.0 0.550
Intervention Linear accelerator 1 1.00 (0.19-5.25) 1.000 — — 0.595
Gamma knife surgery 5 0.72 (0.36-1.45) 0.358 37.0 0.174
Not mentioned 1 1.23 (0.41-3.69) 0.712 — —
Follow-up (months) ≥ 60 4 1.40 (0.71-2.79) 0.330 0.0 0.732 0.023
< 60 3 0.50 (0.28-0.89) 0.018 0.0 0.622
Study quality High 6 0.82 (0.46-1.46) 0.498 32.3 0.194 0.929
Low 1 0.70 (0.09-5.50) 0.735 — —